{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:31:02Z","timestamp":1793604662143,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.radonc.2023.110043","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T11:31:15Z","timestamp":1701689475000},"page":"110043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0731-8041","authenticated-orcid":false,"given":"Luca","family":"Nicosia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Giaj-Levra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Mazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Pastorello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ricchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Gaetano","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.110043_b0005","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110043_b0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.110043_b0015","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00432-019-02983-3","article-title":"Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients","volume":"145","author":"Nicosia","year":"2019","journal-title":"J Cancer Res Clin Oncol."},{"key":"10.1016\/j.radonc.2023.110043_b0020","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3390\/cancers15041288","article-title":"The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: an analysis of the PACE B Study","volume":"15","author":"Ratnakumaran","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2023.110043_b0025","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/cncr.34836","article-title":"Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: a systematic review and meta-analysis","volume":"129","author":"Leeman","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.110043_b0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/0284186X.2020.1821090","article-title":"Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy","volume":"60","author":"Nicosia","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2023.110043_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109441","article-title":"SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: an analysis of the dosimetric impact of intra-fractional organ changes","volume":"179","author":"Brennan","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110043_b0040","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/j.clon.2022.03.022","article-title":"Prostate Volume Changes during Extreme and Moderately Hypofractionated Magnetic Resonance Image-guided Radiotherapy","volume":"34","author":"Alexander","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"10.1016\/j.radonc.2023.110043_b0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1748-717X-9-22","article-title":"Change in prostate volume during extreme hypo-fractionation analysed with MRI","volume":"9","author":"Gunnlaugsson","year":"2014","journal-title":"Radiat Oncol."},{"key":"10.1016\/j.radonc.2023.110043_b0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.radonc.2021.12.037","article-title":"Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: a post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy","volume":"167","author":"Ma","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110043_b0055","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/0284186X.2022.2062682","article-title":"Radiation-induced prostate swelling during SBRT of the prostate","volume":"61","author":"Vanhanen","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2023.110043_b0060","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13014-019-1308-y","article-title":"MR-guidance in clinical reality: current treatment challenges and future perspectives","volume":"14","author":"Corradini","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110043_b0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13014-020-01510-w","article-title":"1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment","volume":"15","author":"Alongi","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110043_b0070","article-title":"Automated planning for prostate stereotactic body radiation therapy on the 1.5 T MR-Linac","volume":"7","author":"Naccarato","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110043_b0075","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.ijrobp.2006.11.027","article-title":"Prostate volume contouring: a 3D analysis of segmentation using 3DTRUS, CT, and MR","volume":"67","author":"Smith","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110043_b0080","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ijrobp.2011.03.024","article-title":"Greater postimplant swelling in small-volume prostate glands: implications for dosimetry, treatment planning, and operating room technique","volume":"82","author":"Chung","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110043_b0085","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jjco\/hyq118","article-title":"Swelling of the prostate gland by permanent brachytherapy may affect seed migration","volume":"40","author":"Kono","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110043_b0090","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ijrobp.2004.12.012","article-title":"Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion","volume":"62","author":"Taussky","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110043_b0095","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-8140(03)00031-8","article-title":"Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy","volume":"66","author":"Sanguineti","year":"2003","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.radonc.2023.110043_b0100","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110043_b0105","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-023-04579-6","article-title":"State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature","author":"Le Guevelou","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2023.110043_b0110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejmp.2020.09.026","article-title":"Adaptive SBRT by 1.5 T MR-linac for prostate cancer: on the accuracy of dose delivery in view of the prolonged session time","volume":"80","author":"Ruggieri","year":"2020","journal-title":"Physica Medica"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T04:10:02Z","timestamp":1734235802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023093507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":22,"alternative-id":["S0167814023093507"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110043","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110043"}}